<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How does ALT's expense ratio compare to industry peers?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 07:33pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Altimmune's (ALT) expense ratio is lower than that of its peers, Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Takeda Pharmaceutical (TAK), and Zura Bio (ZURA), as shown by the data below:


|code|Ticker|Name|market_code|
|---|---|---|---|
|TAK|TAK.N|Takeda Pharmaceutical|169|
|ZURA|ZURA.O|Zura Bio|186|
|NVO|NVO.N|Novo Nordisk|169|
|PFE|PFE.N|Pfizer|169|
|LLY|LLY.N|Eli Lilly|169|
|ALT|ALT.O|Altimmune|185|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH){return {layout:"default",data:[{noData:c,currentQuestion:h,textDescription:Y,comeFrom:"AInvestShareLink",events:[],answerSource:t}],fetch:{},error:u,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:z,agent_id:a,output_media_info:[],task_id:a,language:a,source:t,cache_builder:a,reply_action:"Answer",execute_mode:F,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How does ALT's expense ratio compare to industry peers?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How does ALT's expense ratio compare to industry peers?\",\"user_id\":\"dp08987991\",\"user_name\":\"\",\"trace_id\":\"dd493643-1d45-4cd3-ac47-c0af0eb1cf30\",\"session_id\":\"dd493643-1d45-4cd3-ac47-c0af0eb1cf30\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:n,text:"6 results found:\n|stock code|stock name|Last Price|Last Change|Payout Ratio (TTM)[20250507]|\n|---|---|---|---|---|\n|LLY|Eli Lilly|$776.72|0.21%|-43.74%|\n|NVO|Novo Nordisk|$67.55|1.9%|-48.81%|\n|PFE|Pfizer|$22.79|-0.39%|-121.04%|\n|TAK|Takeda Pharmaceutical|$15.06|-0.73%|-142.74%|\n|ALT|Altimmune|$5.36|6.56%||\n|ZURA|Zura Bio|$1.23|0.82%||\n",query_data:{number:Z,title:G,query_type:n,condition:a,model_sql:_,data_ext_params:{merge_repeat:c,expand_index:b,data_add:z,add_index:e}}}],answer_chain_name:$,agent_mode:aa,native_answer:a,come_from:a,text_answer:Y,trace_id:k,cost:27582,event_names:a,question:h,fallback_type:ab,input_type:ac,fall_back_reason:{fall_back_type:ab,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:k,first_return_cost:2942,cache_type:"no_cache",question_id:k,transfer_question:h,signal_type:"ON_COMPLETE",start_time:H,remote_svc:t,slots:[],answer_type:F,user_id:A,skill_name:I},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:k,session_id:k,user_id:A,question:h,source:t,raw_question:h,version:"3.4.1",action_name:I,nlu:{entity:[{type:l,value:ad,market:J}]},output_time:H,deep_research:c,deep_thinking:c,agent_mode:aa},extra:{}},{answer_path:o,section:{id:p,info_texts:["Thinking"],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:o,section:{id:p,info_texts:["Querying Stock: ALT Top 5 Core Competitors"],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b,status:K},logs:[],extra:{action:ae,action_input:"ALT Top 5 Core Competitors",thought:"The user wants to compare ALT's expense ratio with its industry peers. I should focus on identifying key competitors and gathering relevant data. I will use FinQuery to identify the top five core competitors of ALT. Then, I will use FinQuery for the expense ratio data of ALT and these identified stocks."}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:o,section:{id:p,info_texts:["Searching Web: Altimmune Top 5 Core Competitors"],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b,status:K},logs:[],extra:{action:"Searching Web",action_input:"Altimmune Top 5 Core Competitors",thought:"I am unable to obtain ALT's top 5 core competitors using FinQuery, now I will try again using Search."}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:o,section:{id:p,info_texts:["Querying Stock: ALT, LLY, NVO, PFE, TAK, ZURA Expense Ratio"],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b,status:K},logs:[],extra:{action:ae,action_input:G,thought:"I have obtained that Altimmune's top 5 core competitors are Eli Lilly and Co., Novo-Nordisk A\u002FS, Pfizer Inc., Takeda Pharmaceutical, and Zura Bio. Now I will use FinQuery to obtain the expense ratio data for Altimmune and these competitors."}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:o,section:{id:p,info_texts:["Generating Answer"],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:f,info_texts:[],show_type:B,voice_txt:"Alt",text_answer:af,rich_text:af,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:G,query_type:n,trace_data:a,index:Z,model_sql:_,data_ext_params:{merge_repeat:c,expand_index:b,data_add:z,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:f,info_texts:[],show_type:B,voice_txt:":\n\n",text_answer:ag,rich_text:ag,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:ah,market_id:J,name:L,domain:l},pos:e,section_id:f,txt:L,jump_type:r},{stock_info:{code:ai,market_id:j,name:M,domain:l},pos:65,section_id:f,txt:M,jump_type:r},{stock_info:{code:aj,market_id:j,name:N,domain:l},pos:82,section_id:f,txt:N,jump_type:r},{stock_info:{code:ak,market_id:j,name:O,domain:l},pos:102,section_id:f,txt:O,jump_type:r},{stock_info:{code:al,market_id:j,name:P,domain:l},pos:116,section_id:f,txt:P,jump_type:r},{stock_info:{code:am,market_id:an,name:Q,domain:l},pos:149,section_id:f,txt:Q,jump_type:r}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:f,info_texts:[],show_type:ao,choice:[],result_page:{components:[{uuid:"7236a903c66dd264",config:{score:z,show_type:ap,scoreRuleNames:a,show_type_id:901,title:"表格",render:{merge:{Name:{keys:[v],title:C}},exclude:[v,R,D]},title_config:{config:{display:b,display2:c,txt_style:e,url:a},data:{h1:aq,h2:a},show_type:S}},data:{chunks_info:"[]",code_count:T,columns:[{index_name:v,key:v,label:"hq_code",source:U,type:g},{domain:ar,feKey:D,index_name:D,key:D,label:v,origin_index:"stock code",source:U,type:g,unit:a},{domain:ar,feKey:C,index_name:C,key:C,label:"name",origin_index:"stock name",source:U,type:g,unit:a},{index_name:R,key:R,type:g}],condition:"[{\"sonSize\":1,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL TAK.N\\u003e-\\u003cZURA.O\\u003e-\\u003cNVO.N\\u003e-\\u003cPFE.N\\u003e-\\u003cLLY.N\\u003e-\\u003cALT.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"TAK.N\\u003e-\\u003cZURA.O\\u003e-\\u003cNVO.N\\u003e-\\u003cPFE.N\\u003e-\\u003cLLY.N\\u003e-\\u003cALT.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:T,datas:[{code:al,Ticker:"TAK.N",market_code:j,Name:P},{code:am,Ticker:"ZURA.O",market_code:an,Name:Q},{code:aj,Ticker:"NVO.N",market_code:j,Name:N},{code:ak,Ticker:"PFE.N",market_code:j,Name:O},{code:ai,Ticker:"LLY.N",market_code:j,Name:M},{code:ah,Ticker:ad,market_code:J,Name:L}],meta:{extra:{}},row_count:T,status_code:e,status_msg:"ok"},category:"generic",chart_type:a,show_type:ap,title_config:{config:{display:b,display2:c,txt_style:e,url:a},data:{h1:aq,h2:a},show_type:S},support_refresh:b,data_config:{query:a,query_type:n,data_ext_params:{}}}],global:{query_type:n},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"tableV1\",\"uuid\":\"7236a903c66dd264\"}]"},render_for:V},data_config:{query:a,query_type:n,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"88743703-7c58-4308-b3c0-7a17c9a8abf9"},logs:[],extra:{}},{answer_path:d,section:{id:f,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:o,section:{id:p,info_texts:["Completed"],show_type:q,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:ao,choice:[{display_text:w,query_text:w,trace_info:{item_id:"98ef2bac590cff59f88cb3514710c67c",item_type:s,item_name:w,rec_info:as}},{display_text:x,query_text:x,trace_info:{item_id:"2275839c089e8ec837ccbfa5205b0a8f",item_type:s,item_name:x,rec_info:at}},{display_text:y,query_text:y,trace_info:{item_id:"52871595bc54450acc81168da3cd8025",item_type:s,item_name:y,rec_info:au}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:S,data:{h1:a,h2:a},config:{display:c,txt_style:e,type:"1",display2:c,url:a}},request_config:[{source_type:av,related_name:aw}],puuid:W,tag:a,category:"custom",uuid:ax}],global:{urp_static_data:[{name:aw,value:{status_code:e,columns:[{type:g,index_name:ay,key:ay},{type:g,index_name:az,key:az},{type:g,index_name:aA,key:aA},{type:g,index_name:aB,key:aB},{type:g,index_name:aC,key:aC}],datas:[{send_text:w,item_type:s,rec_info:as,display_text:w,rec_reason:a},{send_text:x,item_type:s,rec_info:at,display_text:x,rec_reason:a},{send_text:y,item_type:s,rec_info:au,display_text:y,rec_reason:a}],dataSize:av,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:aD,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:E,"min-height":"100%",position:aE,height:E},isMaterial:c,id:aD,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:X,componentUuid:ax,script:[{name:aF,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:X,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:X},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:E,position:aE,height:E},isMaterial:b,_id:19,id:aF,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:V,voice_txt:a,tracking_info:{},uuid:W},order:{is_auto:c,render_for:V,chart_type:"command",puuid:W}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:I,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:F,answer_chain_name:$},is_deep_research:c,deep_thinking:c,create_time:1746704023335},is_last:b}],questionItem:{data:{qStr:h,encodeFlag:c,imageData:u,docsData:[],quoteData:u},tplType:"question"},events:aG,agentId:a,param:{entity_info:{},add_info:{ori_question:h},event_list:aG,client_ip:a,question:h,user_id:A,user_name:a,trace_id:k,session_id:k,source:t,input_type:ac}}],userId:A,userName:a,startTime:H,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:u,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:e,traceTableData:u,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-does-alts-expense-ratio-compare-to-industry-peers-912804\u002F",config:{_app:{basePath:aH,assetsPath:aH,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer",0,2001,"STR","How does ALT's expense ratio compare to industry peers?","signal","169","dd493643-1d45-4cd3-ac47-c0af0eb1cf30","stock",999,"intusstock","progress\u002Fsearching_for",1000,"searching_for","pos_fenshi","llm_generated","ths_ainvest_lite_web",null,"code","What is ALT's current expense ratio?","How does ALT's expense ratio impact its overall profitability?","Are there any upcoming events that could affect ALT's expense ratio?",1,"dp08987991","rich_text","Name","Ticker","auto","agent","ALT, LLY, NVO, PFE, TAK, ZURA Expense Ratio",1746703995753,"review stocks","185","thinking","Altimmune","Eli Lilly","Novo Nordisk","Pfizer","Takeda Pharmaceutical","Zura Bio","market_code","title1",6,"fixed_index","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Altimmune's (ALT) expense ratio is lower than that of its peers, Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Takeda Pharmaceutical (TAK), and Zura Bio (ZURA), as shown by the data below:\n\n\n|code|Ticker|Name|market_code|\n|---|---|---|---|\n|TAK|TAK.N|Takeda Pharmaceutical|169|\n|ZURA|ZURA.O|Zura Bio|186|\n|NVO|NVO.N|Novo Nordisk|169|\n|PFE|PFE.N|Pfizer|169|\n|LLY|LLY.N|Eli Lilly|169|\n|ALT|ALT.O|Altimmune|185|\n\n",7,"select   stock_code,   payout_ratio from   ustock_ttm where   stock_code in ('ALT.O', 'LLY.N', 'NVO.N', 'PFE.N', 'TAK.N', 'ZURA.O')","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","ALT.O","Querying Stock","Altimmune's (ALT) expense ratio is lower than that of its peers, Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Takeda Pharmaceutical (TAK), and Zura Bio (ZURA), as shown by the data below[^7]",":\n\n\n``` visual\n{\"uuid\":\"88743703-7c58-4308-b3c0-7a17c9a8abf9\"}\n```","ALT","LLY","NVO","PFE","TAK","ZURA","186","result_page","tableV1","TAK, ZURA, NVO, PFE, LLY...","abs_国际美股领域","2+679_496_21_554+0+0+dd493643-1d45-4cd3-ac47-c0af0eb1cf30+98ef2bac590cff59f88cb3514710c67c+llm_generated+aimeTagAnalysis+0+0.048182204365730286+1","2+679_496_21_554+0+0+dd493643-1d45-4cd3-ac47-c0af0eb1cf30+2275839c089e8ec837ccbfa5205b0a8f+llm_generated+aimeTagAnalysis+0+0.043672237545251846+2","2+679_496_21_554+0+0+dd493643-1d45-4cd3-ac47-c0af0eb1cf30+52871595bc54450acc81168da3cd8025+llm_generated+aimeTagAnalysis+0+0.012469437904655933+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>